ApoE4 and Alzheimer's Disease: Why Some People Stay Healthy
Official title: Study Susceptibility and Resistance to ApoE4 in Alzheimer's Disease
Funded at J. David Gladstone Institutes · NIH-11382206 · Data updated 2026-11-12
A research grant is studying why people with the apoE4 gene develop Alzheimer’s sooner or stay healthy, with the goal of finding new ways to prevent or treat the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | J. David Gladstone Institutes NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project start | July 1, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $879,003 |
| NIH project number | 5R01AG076647-03 |
| Project ID | NIH-11382206 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are individuals, or donors, with apoE4-related risk information or a genetic predisposition study, and patients at risk for Alzheimer’s due to APOE4 status.
✕Less likely to help
People without apoE4 or without a family history of Alzheimer’s may see little direct benefit.
What this research studies
This project looks at how a gene called apoE4 affects brain activity and memory in mouse models to understand who becomes disabled by Alzheimer’s and who does not. Researchers are examining brain signals involved in memory replay and how these signals differ between apoE4 and apoE3 mice as they age. By linking these brain patterns to learning and memory problems, the study aims to uncover new targets for therapies that could help people at risk for Alzheimer’s.
Why it matters
Potential benefit: If successful, the findings could lead to new strategies to delay or prevent Alzheimer’s symptoms in people carrying apoE4.
How similar studies have gone: Early work in animal models has shown apoE4-related brain changes linked to memory; translating these findings to human therapies remains a key challenge.
Where this research is happening
-
J. David Gladstone Institutes
San Francisco, United States Active
Researchers
- Principal investigator: Huang, Yadong — J. David Gladstone Institutes
- Study coordinator: Huang, Yadong
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.